Protecting Pharmacies in Medicaid Act

H.R. 2484 Seniors Access to Critical Medications Act H.R. 2853 Combating Organized Retail Crime Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 526 Pharmacy Benefit Manager (PBM) Transparency Act S. 527 Prescription Pricing for the People Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 1404 Combating Organized Retail Crime Act S. 2426 Equitable Community Access to Pharmacist Services Act S. 3345 PBM Price Transparency and Accountability Act H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act H.R. 6575 CommonGround for Affordable Health Care Act H.R. 6501 Bipartisan Health Insurance Affordability Act H.R. 5256 340B ACCESS Act H.R. 4581 340B PATIENTS Act S. 2372 340B PATIENTS Act H.R. 6400 Rx ACCESS Act S. 4106 Rx ACCESS Act S. 3788 CLEAR LABELS Act S. 4509 Patients Before Monopolies Act H.R. 8779 Patients Before Monopolies Act S. 3822 Break Up Big Medicine Act H.R. 8800 National Defense Authorization Act S. 4784 National Defense Authorization Act S. 3097 Health Information Privacy Reform Act

Client expense: $480,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2484 Seniors Access to Critical Medications Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 2626 Equitable Community Access to Pharmacist Services Act S. 3345 PBM Price Transparency and Accountability Act H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act H.R. 6575 CommonGround for Affordable Health Care Act H.R. 6501 Bipartisan Health Insurance Affordability Act

Client expense: $480,000 · Firm income: Not reported

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 4323/ H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S.2276/ H.R. 3269; Eliminating Thickets to Improve Competition Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 S. 5586; Ensuring Accurate Payments to Specialty Pharmacies Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8324; Great American Healthcare Plan H.R. 9228; Health Data Access, Transparency, and Affordability Act of 2026 H.R. 9486; Health Data Access, Transparency and Affordability Act H.R. 9117; Clear Healthcare Expense Cost Knowledge Act H.R. 9393; Lower Cost, More Transparency Act of 2026 H.R. 9645; Health Care Price Certainty for All Americans Act H.R. 10369; Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3822; Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 S. 5586; Ensuring Accurate Payments to Specialty Pharmacies Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services H.R. 9645; Health Care Price Certainty for All Americans Act H.R. 10369; Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $3,203,049 · Firm income: Not reported

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 2617/H.R. 1244; Reducing Drug Prices for Seniors Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S.4323/ H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 S. 5586; Ensuring Accurate Payments to Specialty Pharmacies Act H.R. 4317; PBM Reform Act H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services H.R. 9393; Lower Costs, More Transparency Act H.R. 9645; Health Care Price Certainty for All Americans Act H.R. 10369; Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $3,203,049 · Firm income: Not reported

Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 "Prescription Pricing for People Act of 2025 IPC supports H.R. 4317/S.3345 PBM Reform Act of 2025 IPC supports H.R. 3164/S. 2426 - "Main Street Pharmacy Access Act" IPC supports H.R. 6609 & H.R. 6610 - Pharmacists Fights Back Act IPC supports H.R. 5256 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act) IPC monitors Trump Administration 340B Rebate Pilot Program adoption and implementation IPC supports OBBBA - Rural Health Transformation Program - grant implementation IPC monitors Senate BI-Partisan 340B working group - draft legislation IPC monitors Trump Administration overseas manufactured drug Section 232 tariffs investigation IPC monitors Trump Administration Drug Pricing Most Favored Nations status/Direct to Consumer (DTC) prescription drug distribution proposals IPC monitors HR 879/S.3794 Safe Drug Act of 2026 IPC is opposed to the HRSA 340B proposed rebate model IPC opposes HR 6509/S. 3794 Safe Drug Act of 2026. IPC opposes HR 5316 the "Drug Shortage Compounding Patient Access Act of 2025" IPC supports the Breakup Big Medicine Act S. 3822 IPC supports Protecting Pharmacies in Medicaid Act S. 927 IPC supports the US Department of Labor proposed rule on PBM transparency [RIN 1210-AB37]

Client expense: $30,000 · Firm income: Not reported

Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 2617/H.R. 1244; Reducing Drug Prices for Seniors Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act H.R. 4317; PBM Reform Act H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services S.4323/ H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $3,282,990 · Firm income: Not reported

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 4323/ H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8324; Great American Healthcare Plan H.R. 9228; Health Data Access, Transparency, and Affordability Act of 2026 H.R. 9486; Health Data Access, Transparency and Affordability Act H.R. 9117; Clear Healthcare Expense Cost Knowledge Act H.R. 9393; Lower Cost, More Transparency Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3822; Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $3,282,990 · Firm income: Not reported

Issues related to Medicare Part D, Medicare Advantage, Medicaid, mental health, and telehealth. Issues related to pharmacy testing, vaccination, and treatment. Issues related to Accountable Care Organizations. Issues related to Medicare Shared Savings Program. Issues related to Medicaid. S. 882, The Patients Before Middlemen (PBM) Act S. 927, The Protecting Pharmacies in Medicaid Act S. 1105 - No Unreasonable Payments, Coding, Or Diagnoses for the Elderly Act S. 3345, The PBM Price Transparency and Accountability Act H.R. 4317, The Pharmacy Benefit Manager (PBM) Reform Act H.R. 4093, Apple to Apples Comparison Act H.R. 6575, CommonGround for Affordable Health Care Act H.R. 6703, The Lower Healthcare Premiums for All Americans Act H.R.6609, Pharmacists Fight Back in Medicare and Medicaid Act

Client expense: $3,570,000 · Firm income: Not reported

Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution

H.R. 2484 Seniors Access to Critical Medications Act H.R. 2853 Combating Organized Retail Crime Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 526 Pharmacy Benefit Manager (PBM) Transparency Act S. 527 Prescription Pricing for the People Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 1404 Combating Organized Retail Crime Act S. 2426 Equitable Community Access to Pharmacist Services Act S. 3345 PBM Price Transparency and Accountability Act H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act H.R. 6575 CommonGround for Affordable Health Care Act H.R. 6501 Bipartisan Health Insurance Affordability Act H.R. 5256 340B ACCESS Act H.R. 4581 340B PATIENTS Act S. 2372 340B PATIENTS Act H.R. 6400 Rx ACCESS Act S. 4106 Rx ACCESS Act S. 3788 CLEAR LABELS Act S. 4509 Patients Before Monopolies Act H.R. 8779 Patients Before Monopolies Act S. 3822 Break Up Big Medicine Act H.R. 8800 National Defense Authorization Act S. 4784 National Defense Authorization Act

Client expense: $290,000 · Firm income: Not reported

H.R. 2484 Seniors Access to Critical Medications Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 2626 Equitable Community Access to Pharmacist Services Act S. 3345 PBM Price Transparency and Accountability Act H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act H.R. 6575 CommonGround for Affordable Health Care Act H.R. 6501 Bipartisan Health Insurance Affordability Act

Client expense: $290,000 · Firm income: Not reported

Proposals addressing pharmacy benefit manager (PBM) practices, including those focused on PBM/pharmacy contracts, pharmacy reimbursement, direct and indirect remuneration (DIR), and transparency Issues relating to pharmacy reimbursement, scope of practice, access to pharmacist-provided care Patients Before Middlemen Act (S. 882) Protecting Pharmacies in Medicaid Act (S. 927) Main Street Pharmacy Access Act (H.R. 3164/S. 2426) PBM Reform Act (H.R. 4317) S.3345 - PBM Price Transparency and Accountability Act H.R.6703 - Lower Health Care Premiums for All Americans Act H.R. 7148 - Consolidated Appropriations Act, 2026 Administration prescription drug pricing platform (Trump Rx)

Client expense: $584,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.891, the Bipartisan Health Care Act; S.882, the Patients Before Middlemen Act; S.927, the Protecting Pharmacies in Medicaid Act; H.R.3164/S.2426, the Mainstreet Pharmacy Access Act/the Ensuring Community Access to Pharmacist Services Act; H.R.2428, the Ensuring Access to Lower-Cost Medicines for Seniors Act; Comments to CMS on the implementation of Medicare Part D Medicare Drug Price Negotiation implementation under the Inflation Reduction Act (IRA; P.L. 117-169); Long-Term Care Pharmacy at Home Services in Medicare; Comments to CMS for its "Dispensing Entity-CMS Agreement and Dispensing Entity-MTF Data Module Contractor Agreement" (IRA; P.L.117-169)' H.R.1, the One Big Beautiful Bill Act Comments to CMS on "Re: Draft Guidance for IPAY 2028 and Manufacturer Effectuation of the MFP for 2026, 2027, and 2028 for the Medicare Drug Price Negotiation Program"; Comments to CMS on "Re: Medicare Transaction Facilitator DRAFT Standard Companion Guide Health Care Claim Payment/Advice (835)" Comments to CMS on "Re: Agency Information Collection Activities: Proposed Collection; Comment Request [Docket No. CMS-10912] - CMS-10912 Medicare Transaction Facilitator for 2026 and 2027 under Sections 11001 and 11002 of the Inflation Reduction Act (IRA) - Drug Price Negotiation Program MTF DM Dispensing Entity and Third-Party Support Enrollment Form"; H.Con.Res.14, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R.4317, the PBM Reform Act; H.R.5031/S.3159, the Preserving Patient Access to Long-Term Care Pharmacies Act; Comments to CMS on "RE:Re: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model [CMS-1830-P]"; Comments to CMS on "Re: Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates; DMEPOS Accreditation Requirements; Provider Enrollment; and Other Medicare and Medicaid Policies [CMS-1828-P]"; Comments to CMS on "RE:Re: 340B Program Notice: Application Process for the 340B Rebate Model Pilot Program [HRSA2025 and HRSA-2025-14619]"; Comments to CMS on "Re: Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program [CMS-1832-P]"; H.R.5256, the 340B ACCESS Act; S.2800, the Pharmacy and Medically Underserved Areas Enhancement Act; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; Grassley-Lujan Request-for-Information on Pharmacists Providing Chronic Care; CMMI Potential reimbursement model for CMS coverage of GLP-1 drugs; H.R.7148, the Consolidated Appropriations Act, 2026; Comments to CMS on Proposed Rule "Re: Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program"; Implementation of "reasonable and relevant" contract terms in the Medicare Part D Program; Comments to CMS on "Re: Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges [CMS-0062-P]"; Comments to CMS on "Re: Medicare GLP-1 Bridge Program - Improper Restriction of the $5.00 LTC Dispensing Fee to Nursing Facility and ICF/IID Residents; Conflict with 42 C.F.R. 423.120, Chapter 5, Section 20.7 of the Medicare Prescription Drug Benefit Manual, and CMSs December 15, 2021 Guidance on LTC Pharmacy Access";

Issues relating to pharmacy benefit managers;; H.R.2214 The DRUG Act; S.927 Protecting Pharmacies in Medicaid Act; S.1967 Patients Before Middlemen Act; S.864 HELP Copays Act; H.R.4317 PBM Reform Act of 2025

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 "Prescription Pricing for People Act of 2025 IPC supports S. 882 Patients Before Middlemen Act IPC supports H.R. 4317/S.3345 PBM Reform Act of 2025 IPC supports H.R. 3164/S. 2426 - "Main Street Pharmacy Access Act" IPC supports H.R. 6609 & H.R. 6610 - Pharmacists Fights Back Act IPC supports H.R. 5256 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act) CMS Plan Year 2027 Medicare Drug Price Negotiation Program list of negotiated drug prices and process for negotiations. IPC monitors Trump Administration 340B Rebate Pilot Program adoption and implementation IPC supports OBBBA - Rural Health Transformation Program - grant implementation IPC monitors Senate BI-Partisan 340B working group - draft legislation IPC monitors Trump Administration overseas manufactured drug Section 232 tariffs investigation IPC monitors Trump Administration Drug Pricing Most Favored Nations status/Direct to Consumer (DTC) prescription drug distribution proposals IPC is opposed to the HRSA 340B proposed rebate model IPC opposes HR 6509/S. 3794 Safe Drug Act of 2026. IPC opposes HR 5316 the "Drug Shortage Compounding Patient Access Act of 2025" IPC supports the Breakup Big Medicine Act S. 3822 IPC supports Protecting Pharmacies in Medicaid Act S. 927 IPC supports the US Department of Labor proposed rule on PBM transparency [RIN 1210-AB37]

Client expense: $40,000 · Firm income: Not reported

S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3822; Break Up Big Medicine Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $2,996,995 · Firm income: Not reported

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 2617/H.R. 1244; Reducing Drug Prices for Seniors Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act H.R. 4317; PBM Reform Act H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $2,996,995 · Firm income: Not reported

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients.

Issues related to Medicare Part D, Medicare Advantage, Medicaid, mental health, and telehealth. Issues related to pharmacy testing, vaccination, and treatment. Issues related to Accountable Care Organizations. Issues related to Medicare Shared Savings Program. Issues related to Medicaid. S. 882, The Patients Before Middlemen (PBM) Act S. 927, The Protecting Pharmacies in Medicaid Act S. 1105 - No Unreasonable Payments, Coding, Or Diagnoses for the Elderly Act S. 3345, The PBM Price Transparency and Accountability Act H.R. 4317, The Pharmacy Benefit Manager (PBM) Reform Act H.R. 4093, Apple to Apples Comparison Act H.R. 6575, CommonGround for Affordable Health Care Act H.R. 6703, The Lower Healthcare Premiums for All Americans Act H.R.6609, Pharmacists Fight Back in Medicare and Medicaid Act

Client expense: $3,320,000 · Firm income: Not reported

Issues relating to pharmacy benefit managers;; H.R.2214 The DRUG Act; S.927 Protecting Pharmacies in Medicaid Act; S.1967 Patients Before Middlemen Act; S.864 HELP Copays Act; H.R.4317 PBM Reform Act of 2025

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Proposals addressing pharmacy benefit manager (PBM) practices, including those focused on PBM/pharmacy contracts, pharmacy reimbursement, direct and indirect remuneration (DIR), and transparency Issues relating to pharmacy reimbursement, scope of practice, access to pharmacist-provided care Inflation Reduction Acts prescription drug price negotiation program and its impact on pharmacy reimbursement Patients Before Middlemen Act (S. 882) Protecting Pharmacies in Medicaid Act (S. 927) Ensuring Community Access to Pharmacist Services Act (H.R. 3164/S. 2426) PBM Reform Act (H.R. 4317) Vaccine administration, reimbursement S.3345 - PBM Price Transparency and Accountability Act H.R.6703 - Lower Health Care Premiums for All Americans Act H.R. 7148 - Consolidated Appropriations Act, 2026

Client expense: $670,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 7148 Consolidated Appropriations Act, 2026 H.R. 2484 Seniors Access to Critical Medications Act H.R. 2853 Combating Organized Retail Crime Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 526 Pharmacy Benefit Manager (PBM) Transparency Act S. 527 Prescription Pricing for the People Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 1404 Combating Organized Retail Crime Act S. 2426 Equitable Community Access to Pharmacist Services Act S. 3345 PBM Price Transparency and Accountability Act H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act H.R. 6575 CommonGround for Affordable Health Care Act H.R. 6501 Bipartisan Health Insurance Affordability Act H.R. 5256 340B ACCESS Act H.R. 4581 340B PATIENTS Act S. 2372 340B PATIENTS Act H.R. 6400 Rx ACCESS Act S. 4106 Rx ACCESS Act S. 3788 CLEAR LABELS Act

Client expense: $320,000 · Firm income: Not reported

H.R. 7148 Consolidated Appropriations Act, 2026 H.R. 2484 Seniors Access to Critical Medications Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 2626 Equitable Community Access to Pharmacist Services Act S. 3345 PBM Price Transparency and Accountability Act H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act H.R. 6575 CommonGround for Affordable Health Care Act H.R. 6501 Bipartisan Health Insurance Affordability Act

Client expense: $320,000 · Firm income: Not reported

S.891, the Bipartisan Health Care Act; S.882, the Patients Before Middlemen Act; S.927, the Protecting Pharmacies in Medicaid Act; H.R.3164/S.2426, the Ensuring Community Access to Pharmacist Services Act; H.R.2428, the Ensuring Access to Lower-Cost Medicines for Seniors Act; Comments to CMS on the implementation of Medicare Part D Medicare Drug Price Negotiation implementation under the Inflation Reduction Act (IRA; P.L. 117-169); Long-Term Care Pharmacy at Home Services in Medicare; Comments to CMS for its "Dispensing Entity-CMS Agreement and Dispensing Entity-MTF Data Module Contractor Agreement" (IRA; P.L.117-169)' H.R.1, the One Big Beautiful Bill Act Comments to CMS on "Re: Draft Guidance for IPAY 2028 and Manufacturer Effectuation of the MFP for 2026, 2027, and 2028 for the Medicare Drug Price Negotiation Program"; Comments to CMS on "Re: Medicare Transaction Facilitator DRAFT Standard Companion Guide Health Care Claim Payment/Advice (835)" Comments to CMS on "Re: Agency Information Collection Activities: Proposed Collection; Comment Request [Docket No. CMS-10912] - CMS-10912 Medicare Transaction Facilitator for 2026 and 2027 under Sections 11001 and 11002 of the Inflation Reduction Act (IRA) - Drug Price Negotiation Program MTF DM Dispensing Entity and Third-Party Support Enrollment Form"; H.Con.Res.14, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R.4317, the PBM Reform Act; H.R.5031/S.3159, the Preserving Patient Access to Long-Term Care Pharmacies Act; Comments to CMS on "RE:Re: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model [CMS-1830-P]"; Comments to CMS on "Re: Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates; DMEPOS Accreditation Requirements; Provider Enrollment; and Other Medicare and Medicaid Policies [CMS-1828-P]"; Comments to CMS on "RE:Re: 340B Program Notice: Application Process for the 340B Rebate Model Pilot Program [HRSA2025 and HRSA-2025-14619]"; Comments to CMS on "Re: Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program [CMS-1832-P]"; H.R.5256, the 340B ACCESS Act; S.2800, the Pharmacy and Medically Underserved Areas Enhancement Act; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; Grassley-Lujan Request-for-Information on Pharmacists Providing Chronic Care; CMMI Potential reimbursement model for CMS coverage of GLP-1 drugs; H.R.7148, the Consolidated Appropriations Act, 2026; Comments to CMS on Proposed Rule "Re: Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program"; Implementation of "reasonable and relevant" contract terms in the Medicare Part D Program;

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 2617/H.R. 1244; Reducing Drug Prices for Seniors Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act H.R. 4317; PBM Reform Act H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $299,699 · Firm income: Not reported

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3822; Break Up Big Medicine Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $299,699 · Firm income: Not reported

Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 "Prescription Pricing for People Act of 2025 IPC supports S. 882 Patients Before Middlemen Act IPC supports H.R. 4317/S.3345 PBM Reform Act of 2025 IPC supports H.R. 3164/S. 2426 - "The Ensuring Community Access to Pharmacists Services (ECAPS) Act IPC supports H.R. 6609 & H.R. 6610 - Pharmacists Fights Back Act IPC supports H.R. 5256 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act) CMS Plan Year 2027 Medicare Drug Price Negotiation Program list of negotiated drug prices and process for negotiations. IPC monitors Trump Administration 340B Rebate Pilot Program adoption and implementation IPC supports OBBBA - Rural Health Transformation Program - grant implementation IPC monitors Senate BI-Partisan 340B working group - draft legislation IPC monitors Trump Administration overseas manufactured drug Section 232 tariffs investigation IPC monitors Trump Administration Drug Pricing Most Favored Nations status/Direct to Consumer (DTC) prescription drug distribution proposals IPC is opposed to the HRSA 340B proposed rebate model IPC supports the Continuing Appropriations Act 2026 (Medicare Part D PBM Reform provisions). IPC supports the Break Up Big Medicine Act S. 3822 IPC supports Protecting Pharmacies in Medicaid Act S. 927

Client expense: $60,000 · Firm income: Not reported

Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients.

S.891, the Bipartisan Health Care Act; S.882, the Patients Before Middlemen Act; S.927, the Protecting Pharmacies in Medicaid Act; H.R.3164/S.2426, the Ensuring Community Access to Pharmacist Services Act; H.R.2428, the Ensuring Access to Lower-Cost Medicines for Seniors Act; Comments to CMS on the implementation of Medicare Part D Medicare Drug Price Negotiation implementation under the Inflation Reduction Act (IRA; P.L. 117-169); Long-Term Care Pharmacy at Home Services in Medicare; Comments to CMS for its "Dispensing Entity-CMS Agreement and Dispensing Entity-MTF Data Module Contractor Agreement" (IRA; P.L.117-169)' H.R.1, the One Big Beautiful Bill Act Comments to CMS on "Re: Draft Guidance for IPAY 2028 and Manufacturer Effectuation of the MFP for 2026, 2027, and 2028 for the Medicare Drug Price Negotiation Program"; Comments to CMS on "Re: Medicare Transaction Facilitator DRAFT Standard Companion Guide Health Care Claim Payment/Advice (835)" Comments to CMS on "Re: Agency Information Collection Activities: Proposed Collection; Comment Request [Docket No. CMS-10912] - CMS-10912 Medicare Transaction Facilitator for 2026 and 2027 under Sections 11001 and 11002 of the Inflation Reduction Act (IRA) - Drug Price Negotiation Program MTF DM Dispensing Entity and Third-Party Support Enrollment Form"; H.Con.Res.14, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R.4317, the PBM Reform Act; H.R.5031/S.3159, the Preserving Patient Access to Long-Term Care Pharmacies Act; Comments to CMS on "RE:Re: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model [CMS-1830-P]"; Comments to CMS on "Re: Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates; DMEPOS Accreditation Requirements; Provider Enrollment; and Other Medicare and Medicaid Policies [CMS-1828-P]"; Comments to CMS on "RE:Re: 340B Program Notice: Application Process for the 340B Rebate Model Pilot Program [HRSA2025 and HRSA-2025-14619]"; Comments to CMS on "Re: Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program [CMS-1832-P]"; H.R.5256, the 340B ACCESS Act; S.2800, the Pharmacy and Medically Underserved Areas Enhancement Act; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; Grassley-Lujan Request-for-Information on Pharmacists Providing Chronic Care; CMMI Potential reimbursement model for CMS coverage of GLP-1 drugs;

Issues related to Medicare Part D, Medicare Advantage, Medicaid, mental health, and telehealth. Issues related to pharmacy testing, vaccination, and treatment. Issues related to Accountable Care Organizations. Issues related to Medicare Shared Savings Program. Issues related to Medicaid. S. 882, The Patients Before Middlemen (PBM) Act S. 927, The Protecting Pharmacies in Medicaid Act S. 1105 - No Unreasonable Payments, Coding, Or Diagnoses for the Elderly Act S. 3345, The PBM Price Transparency and Accountability Act H.R. 4317, The Pharmacy Benefit Manager (PBM) Reform Act H.R. 4093, Apple to Apples Comparison Act H.R. 6575, CommonGround for Affordable Health Care Act H.R. 6703, The Lower Healthcare Premiums for All Americans Act H.R.6609, The Pharmacists Fight Back in Medicare and Medicaid Act

Client expense: $2,270,000 · Firm income: Not reported

Issues relating to pharmacy benefit managers; H.Con.Res.14 Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; S. CON. RES.__ Setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R.2214 The DRUG Act; S.927 Protecting Pharmacies in Medicaid Act; S.1967 Patients Before Middlemen Act; S.864 HELP Copays Act; H.R.4317 PBM Reform Act of 2025

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1 One Big Beautiful Bill Act H.R. 2484 Seniors Access to Critical Medications Act H.R. 2853 Combating Organized Retail Crime Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 526 Pharmacy Benefit Manager (PBM) Transparency Act S. 527 Prescription Pricing for the People Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 1404 Combating Organized Retail Crime Act S. 2426 Equitable Community Access to Pharmacist Services Act S. 2800 Pharmacy and Medically Underserved Areas Enhancement Act S. 3345 PBM Price Transparency and Accountability Act H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act H.R. 6575 CommonGround for Affordable Health Care Act H.R. 6501 Bipartisan Health Insurance Affordability Act H.R. 5256 340B ACCESS Act

Client expense: $360,000 · Firm income: Not reported

H.R. 2484 Seniors Access to Critical Medications Act H.R. 3164 Ensuring Community Access to Pharmacist Services Act H.R. 4317 PBM Reform Act S. 882 Patients Before Middlemen (PBM) Act S. 927 Protecting Pharmacies in Medicaid Act S. 2626 Equitable Community Access to Pharmacist Services Act S. 2800 Pharmacy and Medically Underserved Areas Enhancement Act S. 3345 PBM Price Transparency and Accountability Act H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act H.R. 6575 CommonGround for Affordable Health Care Act H.R. 6501 Bipartisan Health Insurance Affordability Act

Client expense: $360,000 · Firm income: Not reported